Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies. (PubMed, Mult Scler) - Oct 18, 2026 - "The absence of relative lymphocytosis is associated with anti-drug antibody responses and may provide a simple biomarker to prompt anti-drug antibody testing before disease breakthrough occurs."
Biomarker • Journal • CNS Disorders • Multiple Sclerosis
|
|
Angray S Kang; David Baker; Emma C Tallantyre; Ester Valero-Hernandez; Iris Y H Liu; Jai Mathur; Klaus Schmierer; Sarah L Morgan
|